Devonian Health Group, Inc. (TSE:GSD)
TSXV:GSD
Canadian Market

Devonian Health Group, Inc. (GSD) Stock Price & Analysis

3 Followers

GSD Stock Chart & Stats

Day’s RangeC$0 - C$0
52-Week RangeC$0.13 - C$0.50
Previous CloseC$0.15
Volume13.64K
Average Volume (3M)18.12K
Market Cap
C$22.10M
Enterprise ValueC$20.65M
Total Cash (Recent Filing)C$5.13M
Total Debt (Recent Filing)C$3.68M
Price to Earnings (P/E)-4.7
Beta1.23
Nov 24, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding144,457,805
10 Day Avg. Volume7,649
30 Day Avg. Volume18,116
Standard Deviation0.30
R-Squared0.07
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)5.91
Price to Sales (P/S)53.36
Price to Cash Flow (P/CF)-6.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0


Financials

Annual

GSD FAQ

What was Devonian Health Group, Inc.’s price range in the past 12 months?
Devonian Health Group, Inc. lowest stock price was C$0.13 and its highest was C$0.50 in the past 12 months.
    What is Devonian Health Group, Inc.’s market cap?
    Currently, no data Available
    When is Devonian Health Group, Inc.’s upcoming earnings report date?
    Devonian Health Group, Inc.’s upcoming earnings report date is Nov 24, 2023 which is in 51 days.
      How were Devonian Health Group, Inc.’s earnings last quarter?
      Devonian Health Group, Inc. released its earnings results on Jun 28, 2023. The company reported -C$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.011.
        Is Devonian Health Group, Inc. overvalued?
        According to Wall Street analysts Devonian Health Group, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Devonian Health Group, Inc. pay dividends?
          Devonian Health Group, Inc. does not currently pay dividends.
          What is Devonian Health Group, Inc.’s EPS estimate?
          Devonian Health Group, Inc.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Devonian Health Group, Inc. have?
          Devonian Health Group, Inc. has 144,457,810 shares outstanding.
            What happened to Devonian Health Group, Inc.’s price movement after its last earnings report?
            Devonian Health Group, Inc. reported an EPS of -C$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of Devonian Health Group, Inc.?
              Currently, no hedge funds are holding shares in TSE:GSD

              ---

              Devonian Health Group, Inc. Stock Smart Score

              N/A
              Not Ranked
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Technicals

              SMA
              Negative
              20 days / 200 days
              Momentum
              -59.18%
              12-Months-Change

              Fundamentals

              Return on Equity
              -29.24%
              Trailing 12-Months
              Asset Growth
              -19.93%
              Trailing 12-Months
              This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
              Learn more about TipRanks Smart Score

              Company Description

              Devonian Health Group, Inc.

              Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It is intended to develop prescription botanical drugs which could be from plant materials, algae, macroscopic fungi, and combinations thereof. The company's technology platform, The Supra Molecular Complex Extraction, and Stabilization Technology provide a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. The products of the group include botanical pharmaceuticals, Thykamine; and derma-cosmeceutical product, Purgenesis.

              ---

              Forecast EPS vs Actual EPS


              Similar Stocks
              Company
              Price & Change
              Follow
              Numinus Wellness
              Medexus Pharmaceuticals Inc

              Popular Stocks

              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis